| Literature DB >> 19750101 |
Renée Dallaire1, Eric Dewailly, Daria Pereg, Serge Dery, Pierre Ayotte.
Abstract
BACKGROUND: Several ubiquitous polyhalogenated compounds (PHCs) have been shown to alter thyroid function in animal and in vitro studies. So far, epidemiologic studies have focused on the potential effect of a small number of them, namely, polychlorinated biphenyls (PCBs) and some organochlorines (OCs), without paying attention to other important PHCs.Entities:
Keywords: Inuit; dioxin-like compounds; hydroxylated metabolites; organochlorines; perfluoro-octanesulfonate; polybrominated diphenyl ethers; polychlorinated biphenyls; polyhalogenated compounds; thyroid hormones
Mesh:
Substances:
Year: 2009 PMID: 19750101 PMCID: PMC2737013 DOI: 10.1289/ehp.0900633
Source DB: PubMed Journal: Environ Health Perspect ISSN: 0091-6765 Impact factor: 9.031
Characteristics of adult Inuit of Nunavik.
| Characteristic | No. | Percentage | Mean ± SD | Range |
|---|---|---|---|---|
| Sex (%) | ||||
| Male | 245 | 39.3 | ||
| Female | 378 | 60.7 | ||
| Menopause (% among females) | ||||
| Yes | 52 | 12.5 | ||
| No | 363 | 87.5 | ||
| Age (years) | 623 | 36.8 ± 13.9 | 18–73 | |
| Body mass index (kg/m2) | 623 | 27.4 ± 5.7 | 17.2–48 | |
| Selenium (μmol/L) | 622 | 4.4 ± 3.0 | 1.5–30.0 | |
| No. of cigarettes/day (%) | ||||
| 0 | 136 | 21.8 | ||
| 1–10 | 187 | 30.0 | ||
| 11–24 | 226 | 36.3 | ||
| ≥ 25 | 74 | 11.9 | ||
| Frequency of alcohol consumption (%) | ||||
| Never or yearly | 287 | 49.4 | ||
| Monthly | 148 | 25.8 | ||
| Weekly | 101 | 17.4 | ||
| Daily | 45 | 7.8 | ||
| Fish consumption (g/day) | 563 | 54.7 ± 75.1 | 0–665.6 | |
| Marine mammal consumption (g/day) | 561 | 27.1 ± 44.4 | 0–398.7 | |
| Education (%) | ||||
| None | 46 | 7.4 | ||
| Elementary school | 99 | 15.9 | ||
| High school | 394 | 63.2 | ||
| University | 84 | 13.5 | ||
| TSH (mIU/L) | 623 | 1.18 ± 0.79 | 0.06–6.45 | |
| fT4 (pmol/L) | 621 | 15.5 ± 2.1 | 9.3–22.9 | |
| tT3 (nmol/L) | 621 | 2.14 ± 0.33 | 1.21–3.39 | |
| TBG (μg/mL) | 622 | 24.0 ± 6.0 | 8.0–62.8 | |
| Medication use in the last 6 months (%) | ||||
| Yes | 106 | 17.0 | ||
| No | 517 | 83.0 | ||
Expressed on an annual basis.
Laboratory euthyroid reference range: TSH, 0.27–4.20 mIU/L; fT4, 12–22 pmol/L; tT3, 1.3–3.1 nmol/L ; TBG, 13–30 μg/mL.
Plasma concentrations of PHCs in Inuit participants.
| Analyte | No. | Percent detected | Geometric mean | 95% CI | Range |
|---|---|---|---|---|---|
| PCB congener | |||||
| PCB-74 | 623 | 95.0 | 8.92 | 8.15–9.75 | < LOD–218.77 |
| PCB-99 | 623 | 99.7 | 25.53 | 23.38–27.87 | < LOD–849.53 |
| PCB-105 | 623 | 78.4 | 3.49 | 3.10–3.93 | < LOD–100.74 |
| PCB-118 | 623 | 99.8 | 22.76 | 20.79–24.91 | < LOD–497.09 |
| PCB-138 | 623 | 100 | 78.03 | 71.41–85.26 | 3.66–1388.42 |
| PCB-146 | 623 | 98.7 | 22.15 | 20.14–24.36 | < LOD–589.00 |
| PCB-153 | 623 | 100 | 180.06 | 163.71–198.06 | 5.69–5805.15 |
| PCB-156 | 623 | 87.7 | 6.70 | 5.97–7.51 | < LOD–330.97 |
| PCB-163 | 623 | 99.2 | 26.88 | 24.39–29.63 | < LOD–807.77 |
| PCB-170 | 623 | 99.4 | 25.88 | 23.42–28.61 | < LOD–869.17 |
| PCB-172 | 621 | 78.7 | 3.95 | 3.49–4.47 | < LOD–180.20 |
| PCB-177 | 623 | 82.7 | 3.96 | 3.56–4.41 | < LOD–89.13 |
| PCB-178 | 623 | 90.1 | 7.83 | 7.01–8.73 | < LOD–235.60 |
| PCB-180 | 623 | 100 | 93.28 | 84.53–102.93 | 3.25–3510.34 |
| PCB-183 | 623 | 93.5 | 9.16 | 8.35–10.06 | < LOD–177.74 |
| PCB-187 | 623 | 99.8 | 37.98 | 34.67–41.61 | 1.18–790.66 |
| PCB-194 | 623 | 95.1 | 15.74 | 13.94–17.77 | < LOD–945.49 |
| PCB-201 | 623 | 96.1 | 15.88 | 14.19–17.78 | < LOD–772.27 |
| PCB-203 | 623 | 89.4 | 7.93 | 7.08–8.88 | < LOD–294.20 |
| PCB-206 | 623 | 78.2 | 4.02 | 3.51–4.59 | < LOD–275.81 |
| PCB grouping | |||||
| ∑PCBs | 621 | 635.98 | 579.33–698.18 | 31.47–14260.92 | |
| Mono- | 623 | 45.24 | 41.34–49.51 | 1.80–866.67 | |
| DLCs | 607 | 72.6 | 10.62 | 10.04–11.23 | < LOD–139.30 |
| HO-PCB | |||||
| 3-HO-PCB-138 | 562 | 89.0 | 30.38 | 27.17–33.98 | < LOD–980 |
| 3-HO-PCB-153 | 536 | 97.5 | 36.27 | 32.38–40.63 | < LOD–1,500 |
| 4-HO-PCB-107 | 566 | 99.5 | 173.21 | 158.67–189.08 | < LOD–3,200 |
| 4-HO-PCB-146 | 536 | 99.5 | 136.88 | 123.26–152.01 | < LOD–4,900 |
| 4-HO-PCB-163 | 567 | 94.0 | 11.20 | 10.20–12.29 | < LOD–590 |
| 4-HO-PCB-172 | 550 | 96.6 | 19.19 | 17.30–21.27 | < LOD–790 |
| 4-HO-PCB-187 | 567 | 99.8 | 157.69 | 143.67–173.07 | < LOD–4,300 |
| 4-HO-PCB-199 | 568 | 94.5 | 19.10 | 17.20–21.22 | < LOD–1,200 |
| 4-HO-PCB-202 | 566 | 87.9 | 8.42 | 7.66–9.26 | < LOD–340 |
| 4-HO-PCB-208 | 568 | 75.0 | 5.64 | 5.13–6.21 | < LOD–340 |
| ∑HO-PCBs | 536 | 642.02 | 584.52–705.18 | 39.44–14,610 | |
| MeSO2-PCB | |||||
| 3-MeSO2-PCB-49 | 573 | 93.4 | 26.39 | 23.77–29.30 | < LOD–910 |
| 3-MeSO2-PCB-87 | 573 | 76.5 | 11.23 | 10.04–12.57 | < LOD–610 |
| 3-MeSO2-PCB-101 | 575 | 86.9 | 18.50 | 16.55–20.68 | < LOD–920 |
| ∑MeSO2-PCBs | 573 | 57.54 | 51.71–64.03 | < LOD–2,270 | |
| OC | |||||
| | 623 | 100 | 477.78 | 441.70–516.81 | 12.85–8306.48 |
| HCB | 623 | 99.7 | 61.36 | 56.38–66.78 | < LOD–1245.97 |
| Pentachlorophenol | 567 | 100 | 801.43 | 758.25–847.07 | 140–18,000 |
| β-HCH | 622 | 95.9 | 8.33 | 7.70–9.02 | < LOD–201.94 |
| PBDE | |||||
| BDE-47 | 623 | 57.3 | 2.16 | 1.84–2.54 | < LOD–343.45 |
| BDE-153 | 623 | 73.8 | 2.05 | 1.85–2.27 | < LOD–75.74 |
| Perfluorinated compound
| |||||
| PFOS | 621 | 100 | 18,280 | 17,190–19,440 | 480–470,000 |
Abbreviations: β-HCH, β-hexachlorocyclohexane; DDE, p,p′-dichlorodiphenyldichloroethylene; HCB, hexa chlorobenzene.
Lipid standardized concentrations (μg/kg).
Concentrations in picograms toxic equivalents per gram lipids.
Concentrations on a wet weight basis (ng/L).
Linear regression models of THs and TBG plasma levels with PCB and DLC concentrations (wet weight basis).
| TSH
| fT4 | T3 | TBG
| ||||||
|---|---|---|---|---|---|---|---|---|---|
| Analyte | No. | Unadjusted β | Adjusted β | Unadjusted β | Adjusted β | Unadjusted β | Adjusted β | Unadjusted β | Adjusted β |
| PCB congener
| |||||||||
| PCB-74 | 623 | 0.052 | 0.014 | −0.019 | −0.004 | −0.028 | −0.020 | −0.001 | −0.036 |
| PCB-99 | 623 | 0.054 | 0.022 | −0.015 | 0.003 | −0.025 | −0.012 | −0.004 | −0.034 |
| PCB-105 | 623 | 0.039 | 0.017 | −0.015 | −0.004 | −0.021 | −0.018 | −0.001 | −0.030 |
| PCB-118 | 623 | 0.058 | 0.027 | −0.021 | −0.009 | −0.030 | −0.028 | −0.005 | −0.051 |
| PCB-138 | 623 | 0.046 | 0.000 | −0.016 | 0.000 | −0.027 | −0.015 | −0.001 | −0.028 |
| PCB-146 | 623 | 0.035 | −0.023 | −0.016 | −0.004 | −0.028 | −0.020 | −0.000 | −0.026 |
| PCB-153 | 623 | 0.033 | −0.024 | −0.014 | 0.001 | −0.027 | −0.017 | 0.001 | −0.021 |
| PCB-156 | 623 | 0.021 | −0.035 | −0.012 | −0.003 | −0.022 | −0.014 | 0.005 | −0.003 |
| PCB-163 | 623 | 0.039 | −0.009 | −0.016 | −0.007 | −0.028 | −0.023 | 0.000 | −0.024 |
| PCB-170 | 623 | 0.026 | −0.040 | −0.014 | −0.004 | −0.026 | −0.016 | 0.007 | −0.000 |
| PCB-172 | 621 | 0.025 | −0.019 | −0.010 | 0.000 | −0.022 | −0.014 | 0.004 | −0.005 |
| PCB-177 | 623 | 0.036 | −0.006 | −0.014 | −0.002 | −0.024 | −0.015 | 0.001 | −0.018 |
| PCB-178 | 623 | 0.021 | −0.039 | −0.014 | −0.007 | −0.025 | −0.019 | 0.003 | −0.008 |
| PCB-180 | 623 | 0.020 | −0.059 | −0.012 | 0.001 | −0.025 | −0.011 | 0.007 | −0.000 |
| PCB-183 | 623 | 0.031 | −0.024 | −0.012 | 0.006 | −0.025 | −0.011 | 0.003 | −0.017 |
| PCB-187 | 623 | 0.040 | −0.013 | −0.017 | −0.006 | −0.029 | −0.018 | 0.001 | −0.023 |
| PCB-194 | 623 | 0.008 | −0.069 | −0.011 | −0.003 | −0.021 | −0.012 | 0.007 | 0.005 |
| PCB-201 | 623 | 0.016 | −0.051 | −0.012 | −0.003 | −0.024 | −0.016 | 0.006 | −0.003 |
| PCB-203 | 623 | 0.008 | −0.069 | −0.010 | 0.003 | −0.021 | −0.008 | 0.006 | −0.000 |
| PCB-206 | 623 | 0.001 | −0.075 | −0.009 | 0.004 | −0.017 | −0.003 | 0.011 | 0.013 |
| PCB grouping
| |||||||||
| ∑PCBs | 623 | 0.029 | −0.040 | −0.015 | −0.003 | −0.029 | −0.020 | 0.003 | −0.017 |
| Mono- | 623 | 0.051 | 0.009 | −0.021 | −0.012 | −0.031 | −0.028 | 0.001 | −0.037 |
| DLCs | 607 | 0.092 | 0.019 | −0.017 | 0.007 | −0.043 | −0.027 | −0.002 | −0.027 |
All models adjusted for sex, age, body mass index, plasma lipids, cigarette consumption (cigarettes/day), and education. Associations remained significant after adjusting for fish and alcohol consumption, unless noted.
Borderline significant after adjusting for fish consumption (0.05 < p < 0.07).
Not significant after adjusting for alcohol consumption.
Not significant after adjusting for fish consumption.
p ≤ 0.05.
p < 0.01.
p < 0.001.
Linear regression models of THs and TBG plasma levels with OCPs, PBDE, and PFOS concentrations (wet weight basis).
| TSH
| fT4 | T3 | TBG
| ||||||
|---|---|---|---|---|---|---|---|---|---|
| Analyte | No. | Unadjusted β | Adjusted β | Unadjusted β | Adjusted β | Unadjusted β | Adjusted β | Unadjusted β | Adjusted β |
| OC
| |||||||||
| | 623 | 0.051 | 0.012 | −0.021 | −0.007 | −0.030 | −0.016 | −0.001 | −0.030 |
| HCB | 623 | 0.048 | 0.010 | −0.026 | −0.017 | −0.033 | −0.030 | −0.006 | −0.054 |
| Pentachlorophenol | 567 | 0.008 | −0.001 | 0.022 | 0.014 | −0.008 | −0.009 | −0.037 | −0.021 |
| β-HCH | 622 | 0.081 | 0.047 | −0.022 | −0.008 | −0.032 | −0.028 | −0.007 | −0.051 |
| PBDE
| |||||||||
| BDE-47 | 623 | 0.000 | −0.002 | 0.002 | 0.001 | 0.010 | 0.008 | 0.002 | 0.003 |
| BDE-153 | 623 | 0.017 | −0.009 | 0.007 | 0.009 | −0.001 | 0.005 | −0.002 | 0.005 |
| Perfluorinated compound
| |||||||||
| PFOS | 621 | −0.017 | −0.102 | 0.004 | 0.014 | −0.030 | −0.017 | −0.026 | −0.034 |
All models adjusted for sex, age, body mass index, plasma lipids, cigarette consumption (cigarettes/day), and education. Associations remain significant after adjusting for fish and alcohol consumption unless noted.
Borderline significant after adjusting for alcohol consumption (0.05 < p < 0.07).
Borderline significant after adjusting for fish consumption (0.05 < p < 0.07).
p ≤ 0.05.
p < 0.01.
p< 0.001.
Linear regression models of THs and TBG plasma levels with HO-PCB and MeSO2-PCB concentrations (wet weight basis).
| TSH
| fT4 | T3 | TBG
| ||||||
|---|---|---|---|---|---|---|---|---|---|
| Analyte | No. | Unadjusted β | Adjusted β | Unadjusted β | Adjusted β | Unadjusted β | Adjusted β | Unadjusted β | Adjusted β |
| HO compound
| |||||||||
| 3-HO-PCB-138 | 562 | 0.033 | −0.009 | −0.014 | −0.003 | −0.031 | −0.027 | −0.002 | −0.021 |
| 3-HO-PCB-153 | 536 | 0.029 | −0.017 | −0.009 | 0.008 | −0.028 | −0.023 | −0.001 | −0.027 |
| 4-HO-PCB-107 | 566 | 0.020 | −0.020 | −0.011 | 0.009 | −0.029 | −0.013 | −0.016 | −0.052 |
| 4-HO-PCB-146 | 536 | 0.025 | −0.025 | −0.014 | −0.003 | −0.028 | −0.018 | 0.000 | −0.023 |
| 4-HO-PCB-163 | 567 | 0.023 | −0.052 | −0.015 | −0.002 | −0.032 | −0.020 | −0.004 | −0.023 |
| 4-HO-PCB-172 | 550 | 0.027 | −0.028 | −0.012 | 0.002 | −0.031 | −0.024 | −0.001 | −0.021 |
| 4-HO-PCB-187 | 567 | 0.023 | −0.052 | −0.014 | −0.000 | −0.033 | −0.022 | −0.006 | −0.029 |
| 4-HO-PCB-199 | 568 | 0.008 | −0.084 | −0.010 | 0.003 | −0.027 | −0.014 | 0.001 | −0.008 |
| 4-HO-PCB-202 | 566 | 0.019 | −0.056 | −0.013 | −0.001 | −0.033 | −0.023 | −0.001 | −0.016 |
| 4-HO-PCB-208 | 568 | 0.006 | −0.084 | −0.011 | 0.002 | −0.027 | −0.011 | 0.003 | −0.007 |
| ∑HO-PCBs | 536 | 0.035 | −0.025 | −0.015 | 0.000 | −0.033 | −0.025 | −0.002 | −0.034 |
| MeSO2-PCB
| |||||||||
| 3-MeSO2-PCB-49 | 573 | 0.040 | −0.007 | −0.018 | −0.008 | −0.028 | −0.019 | 0.003 | −0.011 |
| 3-MeSO2-PCB-87 | 573 | 0.040 | 0.002 | −0.018 | −0.010 | −0.026 | −0.017 | 0.003 | −0.011 |
| 3-MeSO2-PCB-101 | 575 | 0.037 | −0.009 | −0.017 | −0.008 | −0.026 | −0.016 | 0.006 | −0.004 |
| ∑MeSO2-PCBs | 573 | 0.041 | −0.006 | −0.018 | −0.009 | −0.028 | −0.018 | 0.005 | −0.008 |
All models adjusted for sex, age, body mass index, plasma lipids, cigarette consumption (cigarettes/day), and education. Associations remained significant after adjusting for fish and alcohol consumption unless noted.
Not significant after adjusting for fish consumption.
Borderline significant after adjusting for fish consumption (0.05 < p < 0.07).
p ≤ 0.05.
p < 0.01.
p < 0.001.